Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis

BACKGROUND: In 2014 and 2015, biosimilars for the drugs filgrastim, infliximab, and insulin glargine were approved for use in Canada. The introduction of biosimilars in Canada could provide significant cost savings for the Canadian healthcare system over originator biologic drugs, however it is know...

Descripción completa

Detalles Bibliográficos
Autores principales: Mansell, Kerry, Bhimji, Hishaam, Eurich, Dean, Mansell, Holly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852752/
https://www.ncbi.nlm.nih.gov/pubmed/31718624
http://dx.doi.org/10.1186/s12913-019-4680-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852752/
https://www.ncbi.nlm.nih.gov/pubmed/31718624
http://dx.doi.org/10.1186/s12913-019-4680-2

Ejemplares similares